CHAPTER 1 - MARKET SUMMARY
Market Overview
The China Insulin Market serves a structurally large diabetes population, with approximately 148 million adults living with diabetes in 2024. Around 10 million patients use insulin, creating a recurring pharmaceutical demand pool across type 1 diabetes and insulin-requiring type 2 diabetes. Commercial performance therefore depends on treatment initiation, persistence, dose intensity and mix rather than diabetes prevalence alone.
East and Coastal China represents the strongest commercial concentration in the report's geographic framework, reflecting dense tertiary-care networks, pharmaceutical manufacturing clusters and large urban diabetes populations. Distribution itself is national: more than 35,000 medical institutions submitted demand exceeding 240 million insulin units in the 2024 continuation procurement, giving leading suppliers broad institutional reach rather than dependence on one metropolitan market.
Market Value
USD 2,950 million
2025
Dominant Region
East and Coastal China
Dominant Segment
Insulin Analogs
fastest growing
Total Number of Players
13
Future Outlook
The China Insulin Market is projected to expand from USD 2,950 million in 2025 to USD 3,883 million by 2032, representing a 4.00% CAGR during 2025-2032. The forecast represents a normalization phase following the sharp procurement-led repricing that reduced market value from its 2020 peak. Historical market value therefore records a -7.54% CAGR during 2020-2025, even as treated volume increased. Future value creation is expected to rely on higher insulin utilization, continuing migration toward analog formulations, once-weekly basal innovation and gradual domestic manufacturer share gains rather than restoration of pre-procurement pricing.
Volume is expected to expand faster than market value as centralized procurement continues to restrain realized price per unit. The modeled annual insulin volume rises from approximately 365 million units in 2025 to about 520 million units by 2032, while the blended realized value per unit gradually declines. This creates a scale-oriented operating environment in which manufacturing efficiency, tender positioning, formulation mix and hospital access are decisive. Long-acting, ultra-long and convenient pen-based formulations should capture a rising share of value, while GLP-1 and GIP/GLP-1 therapies create substitution pressure in selected type 2 diabetes cohorts.
4.00%
Forecast CAGR
$3,883 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
-7.54%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, tender exposure, analog mix, margins, localization, pipeline
Corporates
contracted volume, portfolio breadth, pricing, market access, capacity
Government
affordability, supply security, treatment access, quality, reimbursement, localization
Operators
tender execution, distribution, forecasting, cold chain, hospital access, inventory
Financial institutions
revenue resilience, procurement concentration, cash flow, capex, margins, risk
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
The historical period is defined by a major price-led structural reset rather than a contraction in clinical need. The modeled 2020 market peak of USD 4,365 million fell sharply as centralized procurement repriced major insulin products, reaching a trough of USD 2,710 million in 2023. By 2024, market value recovered to USD 2,837 million as higher treatment volumes, analog migration and improved hospital access began offsetting lower realized prices. The 2025 base value of USD 2,950 million therefore represents the normalization of post-procurement economics rather than a return to pre-procurement price levels.
Forecast Market Outlook (2025-2032)
The forecast assumes a stable post-reset pricing structure with value expansion driven primarily by unit growth and product mix. Market value reaches USD 3,883 million by 2032 at a 4.00% CAGR. Modeled insulin volume increases faster than value, reaching approximately 520 million annual units by 2032, reflecting improved access and treatment persistence. Rising analog penetration, once-weekly basal formulations and domestic supplier scaling support revenue growth, while centralized procurement and GLP-1 substitution limit upside. The result is a moderate value-growth market with substantially stronger underlying pharmaceutical consumption than the historical value series alone suggests.
CHAPTER 5 - Market Data
Market Breakdown
The China Insulin Market has transitioned from a high-price, multinational-led structure toward a higher-volume procurement market. For CEOs and investors, the decisive metrics are now treated volume, insulin analog mix and domestic manufacturer participation rather than headline list-price expansion.
Year | Market Size (USD Mn) | YoY Growth (%) | Annual Insulin Units (Mn) | Insulin Analog Share (%) | Domestic Manufacturer Value Share (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $4,365 Mn | +- | 250 | 58% | Forecast | |
| 2021 | $4,280 Mn | +-1.9% | 255 | 59% | Forecast | |
| 2022 | $3,560 Mn | +-16.8% | 290 | 62% | Forecast | |
| 2023 | $2,710 Mn | +-23.9% | 340 | 67% | Forecast | |
| 2024 | $2,837 Mn | +4.7% | 350 | 70% | Forecast | |
| 2025 | $2,950 Mn | +4.0% | 365 | 72% | Forecast | |
| 2026 | $3,068 Mn | +4.0% | 385 | 74% | Forecast | |
| 2027 | $3,191 Mn | +4.0% | 405 | 76% | Forecast | |
| 2028 | $3,319 Mn | +4.0% | 426 | 78% | Forecast | |
| 2029 | $3,452 Mn | +4.0% | 448 | 80% | Forecast | |
| 2030 | $3,590 Mn | +4.0% | 471 | 82% | Forecast | |
| 2031 | $3,733 Mn | +4.0% | 495 | 84% | Forecast | |
| 2032 | $3,883 Mn | +4.0% | 520 | 86% | Forecast |
Annual Insulin Units
approximately 350 million units, post-procurement annualized use. Public-hospital insulin use increased materially after the first national procurement, while the 2024 continuation tender collected more than 240 million units of declared demand from over 35,000 institutions, supporting a volume-led market outlook.
Insulin Analog Share
70% usage share after procurement. Third-generation insulin usage rose from 58% before national procurement to 70% afterward as price gaps narrowed, demonstrating that affordability reform can accelerate quality and formulation mix upgrades rather than merely transfer volume toward lower-cost legacy products.
Domestic Manufacturer Value Share
38% modeled value share in 2024. Hospital procurement demand provides an even stronger localization signal: domestic-company products represented approximately 45% of reported continuation-procurement demand, around 14 percentage points above the first round, supporting further domestic value-share expansion.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, patient requirements, institutional purchasing and pharmaceutical distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Technology
Product Type
Care Setting
End User
Disease Area
Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions provides insight into pharmaceutical mix, care pathways, procurement behavior, patient requirements and access models.
Product Type
Product type is the central commercial axis because national procurement directly differentiates human insulin, rapid analog, basal analog and premixed categories. Long-acting and ultra-long analogs increasingly shape portfolio economics as treatment quality, dosing convenience and adherence become more important after broad price compression. Human insulin remains relevant where cost sensitivity and institutional procurement dominate purchasing decisions.
Technology
Technology is the fastest-evolving dimension as reusable cartridges, prefilled pens and once-weekly basal formulations reduce injection burden and improve treatment convenience. The competitive advantage is shifting from simple molecule availability toward dosing frequency, device compatibility, patient usability and manufacturing economics. Pump-compatible rapid formulations also support premium niches among intensively managed type 1 diabetes patients.
CHAPTER 7 - Regional Analysis
Regional Analysis
China is the largest insulin pharmaceutical market among the selected Asian peer countries, supported by the world's largest adult diabetes population and a nationwide centralized procurement system. Market value growth is more moderate than in selected faster-growing peers because China has already completed a substantial procurement-led price reset.
Focus Country Ranking
1st among selected peers
Focus Country Market Size
USD 2,837 million (2024)
China CAGR (2025-2032)
4.00%
Focus Country Ranking
1st among selected peers
Focus Country Market Size
USD 2,837 million (2024)
China CAGR (2025-2032)
4.00%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | China | Japan | India | South Korea | Indonesia |
|---|---|---|---|---|---|
| Market Size (2024, USD Mn) | 2,837 | 1,280 | 769 | 612 | 166 |
| CAGR (%) | 4.00% | 3.70% | 5.63% | 6.60% | 4.14% |
| Adult Diabetes Cases (2024, Mn) | 148.0 | 9.0 | 89.8 | 5.0 | 20.4 |
| Pricing / Reimbursement Mechanism | National volume-based procurement and public insurance | National Health Insurance price schedule | Mixed public procurement and private retail | National Health Insurance reimbursement | National health insurance formulary and public procurement |
Market Position
China ranks first in the selected peer set with a 2024 pharmaceutical insulin market of USD 2,837 million and approximately 148 million adults with diabetes, giving it unmatched underlying treatment scale.
Growth Advantage
China's 4.00% base-case growth is above Japan's published 3.7% rate but below faster peer rates reported for India and South Korea, positioning China as a large, moderate-growth market rather than a pure high-growth market.
Competitive Strengths
China combines procurement scale with broad supplier participation: more than 35,000 institutions reported over 240 million units of demand and 49 of 53 submitted products secured selection in the 2024 continuation round.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the China Insulin Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution and patient treatment segments.
Growth Drivers
Large Diabetes Population Sustains a Deep Treatment Pool
- Approximately 10 million people use insulin (2024, China), creating a recurring pharmaceutical demand base across type 1 diabetes and insulin-requiring type 2 diabetes.
- Public-hospital insulin use increased from approximately 250 million units annually before procurement to about 350 million units annualized afterward (2024, China), showing affordability can expand treated volume even when market value is price-constrained.
- Third-generation insulin usage increased to 70% after procurement (2024, China) from 58% previously, shifting revenue pools toward higher-quality analog formulations.
National Procurement Expands Access and Institutional Reach
- More than 35,000 medical institutions participated (2024, China), giving selected manufacturers national access while increasing the importance of tender execution, distribution and supply reliability.
- Institutions declared demand exceeding 240 million units (2024, China), giving manufacturers substantial contracted-volume visibility across major insulin categories.
- The continuation tender selected 49 of 53 submitted products, a 92% selection rate (2024, China), supporting broad supply availability while preserving competitive pressure across manufacturers.
National Diabetes Management Policy Broadens Diagnosis and Treatment
- The policy targets at least 70% standardized primary-care management for type 2 diabetes patients by 2030 (China), strengthening longitudinal treatment pathways beyond tertiary hospitals.
- The diabetes action plan was jointly issued by 14 national departments (2024, China), demonstrating cross-agency coordination across healthcare, insurance, technology and public-health implementation.
- Policy explicitly supports digital and innovative diabetes-management technologies through 2030 implementation targets (China), increasing potential for insulin companies that integrate adherence support, connected care and primary-care education.
Market Challenges
Centralized Procurement Compresses Price and Revenue Per Unit
- The 2024 continuation round reduced selected prices by another 3.8 percentage points (2024, China), limiting the scope for manufacturers to rebuild revenue through price increases.
- Tonghua Dongbao reported a 34.66% decline in total revenue in 2024, with insulin tender repricing and channel inventory adjustment cited as major operating factors, illustrating the earnings volatility created by procurement transitions.
- Gan & Lee reported a 74.83% pharmaceutical manufacturing gross margin in 2024, indicating that portfolio mix and manufacturing economics remain critical differentiators even under procurement-led price compression.
GLP-1 and GIP/GLP-1 Therapies Compete for Type 2 Diabetes Intensification
- Injectable semaglutide was approved for type 2 diabetes in China in 2021 (China), establishing a major GLP-1 competitor several years before the insulin forecast base year.
- Greater China Ozempic sales reached approximately USD 698 million equivalent in 2023, illustrating commercial scale for non-insulin injectable diabetes therapies competing for eligible type 2 diabetes patients.
- A domestically developed once-weekly GLP-1 therapy received market approval in 2025 (China), broadening local competition beyond multinational incretin products.
High Tender Participation Intensifies Portfolio Competition
- Lower-priced A-class products represented approximately 71% of selected products in the continuation round (2024, China), increasing rewards for firms capable of balancing tender price with scale economics.
- Domestic products accounted for approximately 45% of hospital-reported procurement demand (2024, China), intensifying competition for multinational incumbents while increasing rivalry among Chinese manufacturers.
- The three largest multinational insulin suppliers historically held around 70% market share before the localization shift (China), so current competition represents structural redistribution rather than simple market expansion.
Market Opportunities
Once-Weekly Basal Insulin Creates a New Convenience Segment
- The approved formulation distributes glucose-lowering activity across a one-week dosing interval (2025, China), reducing injection frequency versus daily basal insulin and creating a differentiated adherence proposition.
- Third-generation insulin already represented 70% of post-procurement use (China), indicating that clinicians and institutions can migrate toward higher-convenience analog technologies when price gaps are manageable.
- A once-weekly basal product reduces routine basal injection occasions from 7 to 1 per week, creating potential value in adherence-sensitive adult populations despite centralized procurement pressure on unit pricing.
Domestic Substitution Expands Addressable Volume for Local Manufacturers
- Gan & Lee secured approximately 46.86 million units of contracted procurement volume (2024, China), 32.6% above its previous contracted quantity, demonstrating monetizable scale from aggressive tender participation.
- Tonghua Dongbao reported total contracted procurement volume of approximately 45 million units (2024, China), providing a three-year volume platform for analog portfolio expansion.
- Domestic products gained approximately 14 percentage points of hospital demand share versus the first procurement round, indicating that localization is structural and can continue where product quality, manufacturing scale and tender execution converge.
Primary-Care Diabetes Management Expands Outpatient Opportunity
- A target of at least 60% diabetes awareness by 2030 (China) should increase diagnosis and treatment entry, expanding the addressable population for glucose-lowering therapy and later-stage insulin intensification.
- The national plan includes 14 issuing departments (2024, China), increasing the probability that diabetes management improvements span insurance, primary care, digital health and public education rather than remaining isolated clinical initiatives.
- Policy support explicitly extends to digital, intelligent and portable diabetes technologies through 2030, creating partnership opportunities around adherence support, glucose monitoring integration and pharmacy-based disease management.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The China Insulin Market combines multinational incumbents with rapidly scaling domestic manufacturers. Centralized procurement has lowered entry barriers to hospital access while raising requirements for manufacturing scale, tender economics, product breadth and reliable national supply.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Novo Nordisk A/S | - | Bagsvaerd, Denmark | 1923 | Basal, rapid, premix and once-weekly insulin analogs |
Gan & Lee Pharmaceuticals Co., Ltd. | - | Beijing, China | 1998 | Domestic insulin analogs, biosimilars and insulin formulations |
Tonghua Dongbao Pharmaceutical Co., Ltd. | - | Tonghua, China | 1985 | Human insulin, basal analogs, rapid analogs and premixed insulin |
Sanofi | - | Paris, France | - | Basal and rapid insulin analogs |
Eli Lilly and Company | - | Indianapolis, United States | 1876 | Rapid, basal and premixed insulin portfolio |
The United Laboratories International Holdings Limited | - | Zhuhai, China | - | Human insulin and insulin analog formulations |
Jiangsu Wanbang Biopharmaceutical Co., Ltd. | - | Xuzhou, China | - | Human insulin and diabetes pharmaceutical products |
Yichang HEC Changjiang Pharmaceutical Co., Ltd. | - | Yichang, China | - | Human insulin and insulin analog formulations |
Hefei Tianmai Biotechnology Development Co., Ltd. | - | Hefei, China | - | Recombinant human insulin products |
Huisheng Biopharmaceutical Co., Ltd. | - | - | - | Insulin analogs and diabetes biologics |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
National VBP Contracted Volume
Analog Insulin Portfolio Breadth
China Insulin Revenue Growth
Gross Margin on Diabetes Biologics
Analysis Covered
Market Share Analysis:
Compares procurement volume, portfolio reach, pricing position and channel presence.
Cross Comparison Matrix:
Benchmarks tender volume, analog breadth, revenue growth and gross margin.
SWOT Analysis:
Assesses technology strengths, VBP exposure, pipeline risks and expansion options.
Pricing Strategy Analysis:
Evaluates tender prices, mix shifts, affordability, rebates and margin resilience.
Company Profiles:
Profiles portfolio scope, tender participation, headquarters, history and market focus.
CHAPTER 10 - REPORT TOC
Table of Contents
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- National insulin procurement volume analysis
- Manufacturer insulin revenue disclosure review
- Diabetes prevalence and treatment mapping
- Insulin portfolio and approval tracking
Primary Research
- Endocrinologists and diabetes center directors
- Hospital pharmacy procurement manager interviews
- Insulin manufacturer commercial leader interviews
- Pharmaceutical distributor market access interviews
Validation and Triangulation
- 290 interviews across value chain
- Tender volume against revenue checks
- Patient demand against consumption checks
- Pricing against procurement mix checks
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
No adjacent reports found.
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals